GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BrightPath Biotherapeutics Co Ltd (TSE:4594) » Definitions » Net Income From Continuing Operations

BrightPath Biotherapeutics Co (TSE:4594) Net Income From Continuing Operations : 円-1,168.08 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is BrightPath Biotherapeutics Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. BrightPath Biotherapeutics Co's net income from continuing operations for the three months ended in Sep. 2024 was 円0.00 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2024 was 円-1,168.08 Mil.

BrightPath Biotherapeutics Co Net Income From Continuing Operations Historical Data

The historical data trend for BrightPath Biotherapeutics Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrightPath Biotherapeutics Co Net Income From Continuing Operations Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,859.86 -1,717.21 -1,481.77 -1,483.73 -1,166.18

BrightPath Biotherapeutics Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -295.76 -258.17 -399.84 -214.32 -

BrightPath Biotherapeutics Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,168.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrightPath Biotherapeutics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BrightPath Biotherapeutics Co Ltd (TSE:4594) » Definitions » Net Income From Continuing Operations
Comparable Companies
TSE:4591 TSE:4881 TSE:2385 TSE:130A TSE:2342 TSE:4576 TSE:4570 TSE:4596 TSE:4598 TSE:4572 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
Website
https://www.brightpathbio.com
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.

BrightPath Biotherapeutics Co Headlines

No Headlines